Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.
作者信息
Altundag Kadri
机构信息
MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey.
出版信息
J BUON. 2021 Sep-Oct;26(5):2202.
PMID:34761636
Abstract
摘要
Zotero 插件